Assessment of a Small Molecule Hepatocyte Growth Factor Mimetic for the Treatment of Parkinson's Disease


To validate the effectiveness and safety of a novel treatment for Parkinson's disease in preparation for clinical testing

Anticipated Impact: 

Prevention and cure of a devastating neurological disease


Parkinson’s disease is a slowly progressing but ultimately incapacitating neurodegenerative disease. Current treatments slow progression of disease, at best. The ability of a unique drug to restore the neurons whose death is responsible for Parkinson’s disease will be evaluated in an animal model. Its ability to treat existing disease, as well as to prevent its frank onset, will be tested. If successful, the drug is expected to be a safe, reasonably inexpensive treatment and possibly a cure for Parkinson’s disease.

Collaborating organizations: Washington State University; Cerep, Inc.; Chantest; SNBL; Infectious Disease Research Institute

Parkinson’s Disease Treatment

Grant Update

Principal Investigator:
Leen Kawas
Grantee Organization:
M3 Biotechnology, Inc.
Grant Title:
Assessment of a small molecule hepatocyte growth factor mimetic for the treatment of Parkinson's disease
Grant Cohort and Year:
2014 Proof of Concept (03)
Grant Period:
08/12/2014 - 08/11/2016 (Completed)
Grant Amount:
This grant allowed to show that our lead compound that we are developing for neurodegeneration, is safe at least in one species. We have developed a simple and inexpensive formulation in preparation for our clinical trials in 2017.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
, 9, 11, 34, 36, 37, 38, 43, 46, 48

Health Impacts

Parkinson's Disease Treatment